| GSK–Spero Therapeutics: tebipenem HBr, 202209– license excl $66m upfront + $375m milestones + royalites ww excl JP + some other Asian countries |
2022-09-22 |
| Spero Therapeutics–GSK: investment, 202209 purchase $9m shares common stock by GSK in connection with licensing of tebipenem HBr |
2022-09-22 |
| Agilent–Scitara: lab informatics, 202209– collab product integration of OpenLab CDS + SLIMS with Scientific Integration Platform SIP + DLX |
2022-09-21 |
| Evotec–Adapsyn Biotechnology: drug discovery, 202209– strategic collab €na providing Evotec with accesss to drug-like small molecules for screening |
2022-09-21 |
| Nuvisan–Gates Foundation: grant, 202209– grant $9.6m for RnD on non-hormonal contraceptive medicines at Nuvisan ICB GmbH |
2022-09-20 |
| Nilogen Oncosystems–Scailyte: personalised medicine, 202209 collab existent developm omics platform for analyzing tumour tissues for I-O developm |
2022-09-19 |
| Scailyte–SEVERAL: investment, 202209 financing round Series A CHF6m with Swiss family office + Mirabaud bank + existing investors |
2022-09-19 |
| Aignostics–SEVERAL: investment, 202209 financing round Series A €14m led by Wellington Partners |
2022-09-15 |
| SparingVision–SEVERAL: investment, 202209 financing round Series B €75m led by Jeito Capital + UPMC Enterprises |
2022-09-15 |
| Capstan Therapeutics–SEVERAL: investment, 202209c recently closed financing round Series A 102$m led by Pfizer Ventures |
2022-09-14 |
| Novo Group–Microsoft: AI-based drug discovery, 202209 collab strategic combining MS computation services + cloud + AI with Novo RnD + data science |
2022-09-12 |
| Pretzel Therapeutics–SEVERAL: investment, 202209 financing round Series A $72.5m led by ARCH Venture Partners + Mubadal Capital |
2022-09-12 |
| Pretzel Therapeutics–Ten Bridge Communications: public relations, 202209 service existent Ten Bridge is media contact |
2022-09-12 |
| Arsenal Biosciences–SEVERAL: investment, 202209 financing round Series B $220m with new + existing investors |
2022-09-06 |
| Abivax–Column Group: investment, 202209 reserved equity capital increase totalling €46.2m incl new + lead investor TCG X |
2022-09-02 |
| Abivax–Deep Track Capital: investment, 202209 reserved equity capital increase totalling €46.2m incl new + co-investor Deep Track Capital |
2022-09-02 |
| Abivax–Invus Group: investment, 202209 reserved equity capital increase totalling €46.2m incl co-investor Invus |
2022-09-02 |
| Abivax–Rockefeller: investment, 202209 reserved equity capital increase totalling €46.2m incl new + co-investor Venrock Healthcare Capital Partners |
2022-09-02 |
| Abivax–SEVERAL: investment, 202209 reserved equity capital increase €46.2m with 5.53m new shares at €8.36/share led by TCG X |
2022-09-02 |
| Forma Therapeutics–Novo Group: investment, 202209– acquisition $1.1b cash tender of by Novo Nordisk at $20/share |
2022-09-01 |
| Novartis–SEVERAL: investment, 202208– spin-off of Sandoz division to be listed on SIX with ADR programme ANNOUNCED |
2022-08-25 |
| CIRM–California (govt): grant, 202208 existent $5.5b in funding from state of California for CIRM |
2022-08-23 |
| CIRM–ElevateBio: iPSC technology, 202208– collab access to iPSC lines + manufacturing capabilities of ElevateBio for CIRM + its grants projects |
2022-08-23 |
| eTheRNA–Novalis LifeSciences: investment, 202208 financing round Series B2 totalling €39m incl existing + lead investor Novalis LifeSciences LLC |
2022-08-23 |
| eTheRNA–Omega Funds: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor Omega Fund |
2022-08-23 |
| eTheRNA–PERSON: investment, 202208 financing round Series B2 totalling €39m incl new + co-investor Kenneth Chien |
2022-08-23 |
| eTheRNA–SEVERAL: investment, 202208 financing round Series B2 €39m led by existing investor Novalis LifeSciences LLC |
2022-08-23 |
| Genome Diagnostics–Eurobio Scientific: investment, 202208– acquisition 100% of GenDx for €135m in cash (net of adjusted cash) |
2022-08-17 |
| ChemDiv–Schaffhausen Institute of Technology: drug discovery, 202208– collab strategic establishment of dedicated research group at Jacobs Univ |
2022-08-11 |
| Vector BioPharma–Versant Ventures: investment, 202208 company emerges with $30m Series A commitment from Versant Ventures |
2022-08-10 |
| B Medical Systems–Azenta: investment, 202208–202210 acquisition $410m upfront + $50m milestones 100% of B Medical from Navis Capital |
2022-08-08 |
| Global Blood Therapeutics–Pfizer: investment, 202208– acquisition $5.4b of GBT in cash at $86.5/share ANNOUNCED |
2022-08-08 |
| Genmab–BioNTech: cancer immunotherapy, 202208– collab expansion 50/50 cost + profit sharing developm + commercn monospeific antibodies using HexaBody |
2022-08-05 |
| 3EO Health–Harvard Univ: nucleic acid diagnostics, 202208– license ww excl from Wyss Institute for portable nucleic acid detection technology |
2022-08-04 |
| ChemoCentryx–Amgen: investment, 202208– acquisition $3.7b at $52/share ANNOUNCED |
2022-08-04 |
| Congenica–GenomOncology: cancer precision diagnostics, 202208– collab developm CE-IVD Precision Oncology Solution using GO Precision Oncology Platform |
2022-08-04 |
| F2G Ltd–Cowen: investment, 202208 financing round totalling $70m inc existing + co-investor Cowen Healthcare Investments |
2022-08-04 |
| F2G Ltd–Novo Group: investment, 202208 financing round totalling $70m inc existing + co-investor Novo Holdings |
2022-08-04 |
| F2G Ltd–SEVERAL: investment, 202208 financing round $70m co-led by new investors Forbion + Sofinnova Partners |
2022-08-04 |
| MiroBio–Gilead Sciences: investment, 202208– acquisition $405m in cash of MiroBio by Gilead ANNOUNCED |
2022-08-04 |
| Scope Fluidics–Bio-Rad: investment, 202208 acquisition $100m upfront + $70m milestones 100% of Curiosity Diagnostics from Scope Fluidics by Bio-Rad |
2022-08-03 |
| Biosynth Carbosynth–Eucodis Bioscience: industrial enzymes, 202208 collab existent for many years |
2022-08-02 |
| Eucodis Bioscience–Biosynth Carbosynth: investment, 202208 acquisition of Eucodis by Biosynth Carbosynth |
2022-08-02 |
| Mementor–ResMed: investment, 202208 acquisition €na of Mementor DE GmbH by ResMed |
2022-08-01 |
| Cleerly–Fidelity: investment, 202207 financing round Series C totalling $223m incl co-lead investor Fidelity Management and Research Company |
2022-07-28 |
| Cleerly–Novartis: investment, 202207 financing round Series C totalling $223m incl new + co-investor Novartis |
2022-07-28 |
| Cleerly–SEVERAL: investment, 202207 financing round Series C $223m led by T Rowe Price + Fidelity |
2022-07-28 |
| Cleerly–T Rowe Price: investment, 202207 financing round Series C totalling $223m incl co-lead investor funds + accounts advised by T Rowe Price |
2022-07-28 |
| Replay–ARTIS Ventures: investment, 202207 seed financing round totalling $55m incl co-investor ARTIS Ventures |
2022-07-25 |
| Replay–Axial: investment, 202207 seed financing round totalling $55m incl co-investor Axial |
2022-07-25 |
| Replay–Consilium: public relations, 202207 service existent by Consilium Strategic Communications |
2022-07-25 |
| Replay–DeciBio Ventures: investment, 202207 seed financing round totalling $55m incl co-investor DeciBio Ventures |
2022-07-25 |
| Replay–KKR: investment, 202207 seed financing round totalling $55m incl co-lead investor KKR Health Care Strategic Growth Fund II |
2022-07-25 |
| Replay–Lansdowne Partners: investment, 202207 seed financing round totalling $55m incl co-investor Lansdowne Partners |
2022-07-25 |
| Replay–OMX Ventures: investment, 202207 seed financing round totalling $55m incl co-lead investor OMX Ventures |
2022-07-25 |
| Replay–SALT: investment, 202207 seed financing round totalling $55m incl co-investor SALT |
2022-07-25 |
| Replay–SEVERAL: investment, 202207 seed financing round $55m led by KKR + OMX Ventures |
2022-07-25 |
| One Medical–Amazon: investment, 202207– acquisition $3.9b in cash of 1Life Healthcare Inc by Amazon at $18/share |
2022-07-21 |
| Delfi Diagnostics–Allianz: investment, 202207 financing round Series B totalling $225m incl existing + co-investor AV8 Ventures |
2022-07-18 |
| Delfi Diagnostics–Brown Advisory: investment, 202207 financing round Series B totalling $225m incl new + co-investor Brown Advisory |
2022-07-18 |
| Delfi Diagnostics–Cowen: investment, 202207 financing round Series B totalling $225m incl existing + co-investor Cowen Healthcare Investments |
2022-07-18 |
| Delfi Diagnostics–Draper Fisher Jurvetson: investment, 202207 financing round Series B totalling $225m incl new + lead investor DFJ Growth |
2022-07-18 |
| Delfi Diagnostics–Foresite Capital: investment, 202207 financing round Series B totalling $225m incl existing + co-investor Foresite Capital |
2022-07-18 |
| Delfi Diagnostics–Illumina: investment, 202207 financing round Series B totalling $225m incl existing + co-investor Illumina Ventures |
2022-07-18 |
| Delfi Diagnostics–Initiate Ventures: investment, 202207 financing round Series B totalling $225m incl new + co-investor Initiate Ventures |
2022-07-18 |
| Delfi Diagnostics–Lilly: investment, 202207 financing round Series B totalling $225m incl new + co-investor Eli Lilly and Co |
2022-07-18 |
| Delfi Diagnostics–Menlo Ventures: investment, 202207 financing round Series B totalling $225m incl existing + co-investor Menlo Ventures |
2022-07-18 |
| Delfi Diagnostics–Northpond Ventures: investment, 202207 financing round Series B totalling $225m incl existing + co-investor Northpond Ventures |
2022-07-18 |
| Delfi Diagnostics–Open Field Capital: investment, 202207 financing round Series B totalling $225m incl new + co-investor Open Field Capital |
2022-07-18 |
| Delfi Diagnostics–OrbiMed: investment, 202207 financing round Series B totalling $225m incl existing + co-investor OrbiMed |
2022-07-18 |
| Delfi Diagnostics–Osage Partners: investment, 202207 financing round Series B totalling $225m incl existing + co-investor Osage University Partners |
2022-07-18 |
| Delfi Diagnostics–Point Field Partners: investment, 202207 financing round Series B totalling $225m incl new + co-investor Point Field Partners |
2022-07-18 |
| Delfi Diagnostics–Point72: investment, 202207 financing round Series B totalling $225m incl new + co-investor Point72 |
2022-07-18 |
| Delfi Diagnostics–PTX Capital: investment, 202207 financing round Series B totalling $225m incl new + co-investor PTX Capital |
2022-07-18 |
| Delfi Diagnostics–Rock Springs Capital: investment, 202207 financing round Series B totalling $225m incl existing + co-investor Rock Springs Capital |
2022-07-18 |
| Delfi Diagnostics–Samsara BioCapital: investment, 202207 financing round Series B totalling $225m incl existing + co-investor Samsara BioCapital |
2022-07-18 |
| Delfi Diagnostics–SEVERAL: investment, 202207 financing round Series B $225m led by DFJ Growth |
2022-07-18 |
| Delfi Diagnostics–T Rowe Price: investment, 202207 financing round Series B totalling $225m incl existing + co-investor T Rowe Price Associates Inc |
2022-07-18 |
| Delfi Diagnostics–Windham Venture Partners: investment, 202207 financing round Series B totalling $225m incl existing + co-investor Windham VP |
2022-07-18 |
| Immunocore–General Atlantic: investment, 202207 private placement totalling $140m incl existing investor General Atlantic |
2022-07-18 |
| Immunocore–Rock Springs Capital: investment, 202207 private placement totalling $140m incl existing investor Rock Springs Capital |
2022-07-18 |
| Immunocore–RTW Investments: investment, 202207 private placement totalling $140m incl existing investor RTW Investments LP |
2022-07-18 |
| Immunocore–SEVERAL: investment, 202207 private placement $140m with 3.73m ADSs/ordinary shares at $37.5/share via PIPE |
2022-07-18 |
| Manifold Biotechnologies–Fifty Years: investment, 202207 financing round Series A totalling $40m incl existing + co-investor Fifty Years |
2022-07-14 |
| Manifold Biotechnologies–FPV Ventures: investment, 202207 financing round Series A totalling $40m incl new + co-investor FPV Ventures |
2022-07-14 |
| Manifold Biotechnologies–Gettylab: investment, 202207 financing round Series A totalling $40m incl existing + co-investor Fast by Gettylab |
2022-07-14 |
| Manifold Biotechnologies–Horizon Ventures: investment, 202207 financing round Series A totalling $40m incl new + co-investor Horizon Ventures |
2022-07-14 |
| Manifold Biotechnologies–Playground Global: investment, 202207 financing round Series A totalling $40m incl existing + co-investor Playground Global |
2022-07-14 |
| Manifold Biotechnologies–Section 32: investment, 202207 financing round Series A totalling $40m incl new + co-investor Section 32 |
2022-07-14 |
| Manifold Biotechnologies–SEVERAL: investment, 202207 financing round Series A $40m led by new investor Triatomic Capital |
2022-07-14 |
| Manifold Biotechnologies–Tencent: investment, 202207 financing round Series A totalling $40m incl new + co-investor Tencent |
2022-07-14 |
| Manifold Biotechnologies–Triatomic Capital: investment, 202207 financing round Series A totalling $40m incl new + lead investor Triatomic Capital |
2022-07-14 |
| Agomab Therapeutics–OTHER: investment, 202207 financing round Series B extension totalling $40.5m incl existing-investors |
2022-07-13 |
| Agomab Therapeutics–Pfizer: investment, 202207 financing round Series B extension totalling $40.5m incl new + lead investor Pfizer Breakthrough GI |
2022-07-13 |
| Agomab Therapeutics–SEVERAL: investment, 202207 financing round Series B extension $40.5m led by Pfizer bringing total Series B to $114m |
2022-07-13 |
| Agomab Therapeutics–Walleye Capital: investment, 202207 financing round Series B extension totalling $40.5m incl new + co-investor Walleye Capital |
2022-07-13 |
| Cergentis–Solvias: investment, 202207 acquisition €na of Cergentis by Solvias |
2022-07-12 |
| Glycomine–Little Dog Communications: public relations, 202207 service existent Little Dog is media contact |
2022-07-11 |
| Exelixis–Ryvu Therapeutics: STING agonists, 202207– license excl $3m upfront fee to develop STING agonist-based targeted cancer therapies |
2022-07-07 |
| Ganymed Robotics–Cathay Capital: investment, 202207 financing round Series B first closing totalling €21m incl lead investor Cathay Health |
2022-07-07 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
